Lupus nephritis.

Biopsy / methods Calcineurin Inhibitors / therapeutic use Cyclophosphamide / therapeutic use Enzyme Inhibitors / therapeutic use Humans Immunosuppressive Agents / therapeutic use Lupus Erythematosus, Systemic / complications Lupus Nephritis / diagnosis Mycophenolic Acid / therapeutic use Polymorphism, Genetic

Journal

Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103

Informations de publication

Date de publication:
23 01 2020
Historique:
accepted: 03 12 2019
entrez: 25 1 2020
pubmed: 25 1 2020
medline: 3 2 2021
Statut: epublish

Résumé

Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most patients with SLE who develop LN do so within 5 years of an SLE diagnosis and, in many cases, LN is the presenting manifestation resulting in the diagnosis of SLE. Understanding of the genetic and pathogenetic basis of LN has improved substantially over the past few decades. Treatment of LN usually involves immunosuppressive therapy, typically with mycophenolate mofetil or cyclophosphamide and with glucocorticoids, although these treatments are not uniformly effective. Despite increased knowledge of disease pathogenesis and improved treatment options, LN remains a substantial cause of morbidity and death among patients with SLE. Within 10 years of an initial SLE diagnosis, 5-20% of patients with LN develop end-stage kidney disease, and the multiple comorbidities associated with immunosuppressive treatment, including infections, osteoporosis and cardiovascular and reproductive effects, remain a concern. Clearly, early and accurate diagnosis of LN and prompt initiation of therapy are of vital importance to improve outcomes in patients with SLE.

Identifiants

DOI: 10.1038/s41572-019-0141-9 PMID: 31974366
pubmed: 31974366
doi: 10.1038/s41572-019-0141-9
pii: 10.1038/s41572-019-0141-9
doi:

Substances chimiques

Calcineurin Inhibitors 0
Enzyme Inhibitors 0
Immunosuppressive Agents 0
Cyclophosphamide 8N3DW7272P
Mycophenolic Acid HU9DX48N0T

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

7

Références

Singh, S., Saxena, R. & Palmer, B. F. Lupus nephritis. Am. J. Med. Sci. 337, 451–460 (2009).
pubmed: 19390431 doi: 10.1097/MAJ.0b013e3181907b3d
Pons-Estel, G. J., Serrano, R., Plasín, M. A., Espinosa, G. & Cervera, R. Epidemiology and management of refractory lupus nephritis. Autoimmun. Rev. 10, 655–663 (2011).
pubmed: 21565286 doi: 10.1016/j.autrev.2011.04.032
Cervera, R. et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 82, 299–308 (2003).
pubmed: 14530779 doi: 10.1097/01.md.0000091181.93122.55
Croca, S. C., Rodrigues, T. & Isenberg, D. A. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology 50, 1424–1430 (2011). An outcome analysis of 156 patients with LN, around 50 from each decade, indicating the trends in mortality, ESKD rate and prevalence of other features over time in a European centre.
pubmed: 21415024 doi: 10.1093/rheumatology/ker101
Bernatsky, S. et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550–2557 (2006).
pubmed: 16868977 doi: 10.1002/art.21955
Moroni, G. et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann. Rheum. Dis. 77, 1318–1325 (2018).
pubmed: 29730634 doi: 10.1136/annrheumdis-2017-212732
Houssiau, F. A. Management of lupus nephritis: an update. J. Am. Soc. Nephrol. 15, 2694–2704 (2004).
pubmed: 15466274 doi: 10.1097/01.ASN.0000140218.77174.0A
Houssiau, F. A. et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50, 3934–3940 (2004).
pubmed: 15593207 doi: 10.1002/art.20666
Houssiau, F. & Ginzler, E. Current treatment of lupus nephritis. Lupus 17, 426–430 (2008).
pubmed: 18490421 doi: 10.1177/0961203308090029
Borchers, A. T., Naguwa, S. M., Shoenfeld, Y. & Gershwin, M. E. The geoepidemiology of systemic lupus erythematosus. Autoimmun. Rev. 9, A277–A287 (2010).
pubmed: 20036343 doi: 10.1016/j.autrev.2009.12.008
Stojan, G. & Petri, M. Epidemiology of systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 30, 144–150 (2018).
pubmed: 29251660 pmcid: 6026543 doi: 10.1097/BOR.0000000000000480
Rees, F., Doherty, M., Grainge, M. J., Lanyon, P. & Zhang, W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology 56, 1945–1961 (2017).
pubmed: 28968809 doi: 10.1093/rheumatology/kex260
Cervera, R. et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine 72, 113–124 (1993).
pubmed: 8479324 doi: 10.1097/00005792-199303000-00005
Kasitanon, N., Magder, L. S. & Petri, M. Predictors of survival in systemic lupus erythematosus. Medicine 85, 147–156 (2006).
pubmed: 16721257 doi: 10.1097/01.md.0000224709.70133.f7
To, C. H. & Petri, M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 52, 4003–4010 (2005).
pubmed: 16320348 doi: 10.1002/art.21414
Seligman, V. A., Lum, R. F., Olson, J. L., Li, H. & Criswell, L. A. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am. J. Med. 112, 726–729 (2002).
pubmed: 12079714 doi: 10.1016/S0002-9343(02)01118-X
Chang, D.-M., Chang, C.-C., Kuo, S.-Y., Chu, S.-J. & Chang, M.-L. The clinical features and prognosis of male lupus in Taiwan. Lupus 7, 462–468 (1998).
pubmed: 9796848 doi: 10.1191/096120398678920479
Mok, C. C., Lau, C. S., Chan, T. M. & Wong, R. W. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. Lupus 8, 188–196 (1999).
pubmed: 10342711 doi: 10.1191/096120399678847605
Garcia, M. A. et al. Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. Lupus 14, 938–946 (2005).
pubmed: 16425573 doi: 10.1191/0961203305lu2245oa
Andrade, R. M. et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 56, 622–630 (2007).
pubmed: 17265497 doi: 10.1002/art.22375
Stefanidou, S. et al. Clinical expression and morbidity of systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male:female comparison. Lupus 20, 1090–1094 (2011).
pubmed: 21700658 doi: 10.1177/0961203311403640
Carreño, L. et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus 8, 287–292 (1999).
pubmed: 10413207 doi: 10.1191/096120399678847786
Bader-Meunier, B. et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J. Pediatr. 146, 648–653 (2005).
pubmed: 15870669 doi: 10.1016/j.jpeds.2004.12.045
Ramírez Gómez, L. et al. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 17, 596–604 (2008).
pubmed: 18539716 doi: 10.1177/0961203307088006
Hoffman, I. E. A. et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann. Rheum. Dis. 68, 412–415 (2009).
pubmed: 18930995 doi: 10.1136/ard.2008.094813
Bastian, H. M. et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 11, 152–160 (2002).
pubmed: 12004788 doi: 10.1191/0961203302lu158oa
Feldman, C. H. et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 65, 753–763 (2013).
pubmed: 23203603 pmcid: 3733212 doi: 10.1002/art.37795
Jakes, R. W. et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res. 64, 159–168 (2012).
doi: 10.1002/acr.20683
Hanly, J. G. et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 55, 252–262 (2016). This multiethnic inception cohort study indicates that LN occurred in 38.3% of patients with SLE and was associated with risk of ESKD and death and lower HRQOL.
pubmed: 26342222 doi: 10.1093/rheumatology/kev311
Maningding, E., Dall’Era, M., Trupin, L., Murphy, L. B. & Yazdany, J. Racial/ethnic differences in prevalence of and time to onset of SLE manifestations: the California lupus surveillance project (CLSP). Arthritis Care Res. https://doi.org/10.1002/acr.23887 (2019). This epidemiological study demonstrates that black, Asian/Pacific Islander and Hispanic individuals are at increased risk of developing severe LN following SLE diagnosis.
doi: 10.1002/acr.23887
Kuo, C.-F. et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern. Med. 175, 1518–1526 (2015).
pubmed: 26193127 doi: 10.1001/jamainternmed.2015.3528
Mohan, C. & Putterman, C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat. Rev. Nephrol. 11, 329–341 (2015).
pubmed: 25825084 doi: 10.1038/nrneph.2015.33
Deng, Y. & Tsao, B. P. Updates in lupus genetics. Curr. Rheumatol. Rep. 19, 68 (2017).
pubmed: 28983873 doi: 10.1007/s11926-017-0695-z
Lo, M. S. Monogenic lupus. Curr. Rheumatol. Rep. 18, 71 (2016).
pubmed: 27812953 doi: 10.1007/s11926-016-0621-9
Goulielmos, G. N. et al. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene 668, 59–72 (2018).
pubmed: 29775752 doi: 10.1016/j.gene.2018.05.041
Imgenberg-Kreuz, J. et al. DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 77, 736–743 (2018).
pubmed: 29437559 pmcid: 5909746 doi: 10.1136/annrheumdis-2017-212379
Souyris, M. et al. TLR7 escapes X chromosome inactivation in immune cells. Sci. Immunol. 3, eaap8855 (2018). This landmark article provides evidence that escape of X chromosome genes from X inactivation can lead to immune activation, and this may explain, in part, the higher prevalence of autoimmunity in females.
pubmed: 29374079 doi: 10.1126/sciimmunol.aap8855
Parks, C. G., de Souza Espindola Santos, A., Barbhaiya, M. & Costenbader, K. H. Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best. Pract. Res. Clin. Rheumatol. 31, 306–320 (2017).
pubmed: 29224673 pmcid: 5729939 doi: 10.1016/j.berh.2017.09.005
Barbhaiya, M. et al. Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the nurses’ health study cohorts. Ann. Rheum. Dis. 77, 196–202 (2018).
pubmed: 28988206 doi: 10.1136/annrheumdis-2017-211675
Petri, M. et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2550–2558 (2005).
pubmed: 16354891 doi: 10.1056/NEJMoa051135
Andreoli, L. et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 76, 476–485 (2017).
pubmed: 27457513 pmcid: 5446003 doi: 10.1136/annrheumdis-2016-209770
Parks, C. & De Roos, A. Pesticides, chemical and industrial exposures in relation to systemic lupus erythematosus. Lupus 23, 527–536 (2014).
pubmed: 24763537 pmcid: 4020505 doi: 10.1177/0961203313511680
Barbhaiya, M. & Costenbader, K. H. Environmental exposures and the development of systemic lupus erythematosus. Curr. Opin. Rheumatol. 28, 497–505 (2016).
pubmed: 27428889 pmcid: 4965307 doi: 10.1097/BOR.0000000000000318
Barbhaiya, M. & Costenbader, K. Ultraviolet radiation and systemic lupus erythematosus. Lupus 23, 588–595 (2014).
pubmed: 24763542 doi: 10.1177/0961203314530488
Wang, B., Shao, X., Wang, D., Xu, D. & Zhang, J.-A. Vaccinations and risk of systemic lupus erythematosus and rheumatoid arthritis: a systematic review and meta-analysis. Autoimmun. Rev. 16, 756–765 (2017).
pubmed: 28483543 doi: 10.1016/j.autrev.2017.05.012
Abdul Kadir, W. D., Jamil, A., Shaharir, S. S., Md Nor, N. & Abdul Gafor, A. H. Photoprotection awareness and practices among patients with systemic lupus erythematosus and its association with disease activity and severity. Lupus 27, 1287–1295 (2018).
pubmed: 29665756 doi: 10.1177/0961203318770016
Silverman, G. J. The microbiome in SLE pathogenesis. Nat. Rev Rheumatol. 15, 72–74 (2019). This is a comprehensive review of microbiome changes in SLE, with a thoughtful discussion of how they may influence disease.
pubmed: 30607012 doi: 10.1038/s41584-018-0152-z
Hevia, A. et al. Intestinal dysbiosis associated with systemic lupus erythematosus. mBio 5, e01548-14 (2014).
pubmed: 25271284 pmcid: 4196225 doi: 10.1128/mBio.01548-14
van der Meulen, T. A. et al. Shared gut, but distinct oral microbiota composition in primary Sjögren’s syndrome and systemic lupus erythematosus. J. Autoimmun. 97, 77–87 (2019).
pubmed: 30416033 doi: 10.1016/j.jaut.2018.10.009
He, Z., Shao, T., Li, H., Xie, Z. & Wen, C. Alterations of the gut microbiome in Chinese patients with systemic lupus erythematosus. Gut Pathog. 8, 64 (2016).
pubmed: 27980687 pmcid: 5146896 doi: 10.1186/s13099-016-0146-9
Lyn-Cook, B. D. et al. Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: ethnic differences and potential new targets for therapeutic drugs. Mol. Immunol. 61, 38–43 (2014).
pubmed: 24865418 doi: 10.1016/j.molimm.2014.05.001
Lee, Y. H., Choi, S. J., Ji, J. D. & Song, G. G. Association between Toll-like receptor polymorphisms and systemic lupus erythematosus: a meta-analysis update. Lupus 25, 593–601 (2016).
pubmed: 26762473 doi: 10.1177/0961203315622823
Devarapu, S. K. & Anders, H.-J. Toll-like receptors in lupus nephritis. J. Biomed. Sci. 25, 35 (2018).
pubmed: 29650017 pmcid: 5898010 doi: 10.1186/s12929-018-0436-2
Sharma, S., Fitzgerald, K. A., Cancro, M. P. & Marshak-Rothstein, A. Nucleic acid-sensing receptors: rheostats of autoimmunity and autoinflammation. J. Immunol. 195, 3507–3512 (2015).
pubmed: 26432899 pmcid: 4593056 doi: 10.4049/jimmunol.1500964
Wang, J. et al. Association of abnormal elevations in IFIT3 with overactive cyclic GMP-AMP synthase/stimulator of interferon genes signaling in human systemic lupus erythematosus monocytes. Arthritis Rheumatol. 70, 2036–2045 (2018).
pubmed: 29806091 doi: 10.1002/art.40576
Kato, Y. et al. Apoptosis-derived membrane vesicles drive the cGAS–STING pathway and enhance type I IFN production in systemic lupus erythematosus. Ann. Rheum. Dis. 77, 1507–1515 (2018).
pubmed: 29945921 pmcid: 6161667
Salvi, V. et al. Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7. JCI Insight 3, e98204 (2018).
pmcid: 6012509 doi: 10.1172/jci.insight.98204 pubmed: 6012509
Dieker, J. et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis: proinflammatory effects of circulating microparticles in SLE. Arthritis Rheumatol. 68, 462–472 (2016).
pubmed: 26360137 doi: 10.1002/art.39417
Sisirak, V. et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell 166, 88–101 (2016).
pubmed: 27293190 pmcid: 5030815 doi: 10.1016/j.cell.2016.05.034
Caielli, S. et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J. Exp. Med. 213, 697–713 (2016). This article ties together the pathogenetic roles of oxidized mitochondrial DNA and type I interferon in SLE.
pubmed: 27091841 pmcid: 4854735 doi: 10.1084/jem.20151876
Gkirtzimanaki, K. et al. IFNα impairs autophagic degradation of mtDNA promoting autoreactivity of SLE monocytes in a STING-dependent fashion. Cell Rep. 25, 921–933.e5 (2018).
pubmed: 30355498 pmcid: 6218203 doi: 10.1016/j.celrep.2018.09.001
Elkon, K. B. Review: cell death, nucleic acids, and immunity: inflammation beyond the grave. Arthritis Rheumatol. 70, 805–816 (2018). This review provides a critical discussion of how aberrant nucleic acid sensing may relate to the pathogenesis of SLE.
pubmed: 29439290 pmcid: 5984680 doi: 10.1002/art.40452
Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 1548–1550 (2016).
pubmed: 27259156 doi: 10.1016/j.cell.2016.05.057
Jourde-Chiche, N. et al. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology 56, 477–487 (2017).
Rother, N. & van der Vlag, J. Disturbed T cell signaling and altered Th17 and regulatory T cell subsets in the pathogenesis of systemic lupus erythematosus. Front. Immunol. 6, 610 (2015).
pubmed: 26648939 pmcid: 4663269 doi: 10.3389/fimmu.2015.00610
Kim, S. J., Lee, K. & Diamond, B. Follicular helper T cells in systemic lupus erythematosus. Front. Immunol. 9, 1793 (2018).
pubmed: 30123218 pmcid: 6085416 doi: 10.3389/fimmu.2018.01793
Zharkova, O. et al. Pathways leading to an immunological disease: systemic lupus erythematosus. Rheumatology 56, i55–i66 (2017).
pubmed: 28375453 doi: 10.1093/rheumatology/kew427
Liu, C.-C., Manzi, S. & Ahearn, J. M. in Dubois’ Lupus Erythematosus and Related Syndromes (eds Wallace, D. J. & Hahn, B. H.) 152–165 (Elsevier, 2013).
Bao, L., Cunningham, P. N. & Quigg, R. J. Complement in lupus nephritis: new perspectives. Kidney Dis. 1, 91–99 (2015).
doi: 10.1159/000431278
Ho, A., Barr, S. G., Magder, L. S. & Petri, M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 44, 2350–2357 (2001).
pubmed: 11665976 doi: 10.1002/1529-0131(200110)44:10<2350::AID-ART398>3.0.CO;2-A
Gandino, I. J. et al. Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. Lupus Sci. Med. 4, e000209 (2017).
pubmed: 29259790 pmcid: 5729297 doi: 10.1136/lupus-2017-000209
Swaak, A. J., Groenwold, J. & Bronsveld, W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann. Rheumatic Dis. 45, 359–366 (1986).
doi: 10.1136/ard.45.5.359
Sturfelt, G. & Truedsson, L. Complement and its breakdown products in SLE. Rheumatology 44, 1227–1232 (2005).
pubmed: 15972354 doi: 10.1093/rheumatology/keh719
Senaldi, G., Makinde, V. A., Vergani, D. & Isenberg, D. A. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 47, 913–917 (1988).
pubmed: 3264693 pmcid: 1003632 doi: 10.1136/ard.47.11.913
Song, D. et al. Complement alternative pathway’s activation in patients with lupus nephritis. Am. J. Med. Sci. 353, 247–257 (2017).
pubmed: 28262211 doi: 10.1016/j.amjms.2017.01.005
Liu, Y. & Anders, H.-J. Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin. Pract. 128, 224–231 (2014).
pubmed: 25401461 doi: 10.1159/000368581
Yu, F., Haas, M., Glassock, R. & Zhao, M.-H. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat. Rev. Nephrol. 13, 483–495 (2017).
pubmed: 28669995 doi: 10.1038/nrneph.2017.85
Kaul, A. et al. Systemic lupus erythematosus. Nat. Rev. Dis. Primers 2, 16039 (2016).
pubmed: 27306639 doi: 10.1038/nrdp.2016.39
Anders, H.-J. Nephropathic autoantigens in the spectrum of lupus nephritis. Nat. Rev. Nephrol. 15, 595–596 (2019).
pubmed: 31197262 doi: 10.1038/s41581-019-0168-x
Doria, A. & Gatto, M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus 21, 1492–1496 (2012).
pubmed: 23042821 doi: 10.1177/0961203312462267
Bruschi, M. et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J. Am. Soc. Nephrol. 26, 1905–1924 (2015).
pubmed: 25398787 doi: 10.1681/ASN.2014050493
Bassi, N. et al. PTX3, anti-PTX3, and anti-C1q autoantibodies in lupus glomerulonephritis. Clin. Rev. Allergy Immunol. 49, 217–226 (2015).
pubmed: 25805362 doi: 10.1007/s12016-015-8476-9
Migliorini, A. & Anders, H.-J. A novel pathogenetic concept — antiviral immunity in lupus nephritis. Nat. Rev. Nephrol. 8, 183–189 (2012).
pubmed: 22249778 doi: 10.1038/nrneph.2011.197
Sciascia, S., Cuadrado, M. J., Khamashta, M. & Roccatello, D. Renal involvement in antiphospholipid syndrome. Nat. Rev. Nephrol. 10, 279–289 (2014).
pubmed: 24642799 doi: 10.1038/nrneph.2014.38
Turner-Stokes, T. et al. Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int. 92, 1223–1231 (2017).
pubmed: 28750930 pmcid: 5652376 doi: 10.1016/j.kint.2017.04.029
Ryu, M. et al. Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non-inflammatory glomerular injury: crescents without glomerular inflammation. J. Pathol. 228, 482–494 (2012).
pubmed: 22553158 doi: 10.1002/path.4046
Sethi, S. et al. Exostosin 1/exostosin 2-associated membranous nephropathy. J. Am. Soc. Nephrol. 30, 1123–1136 (2019). The first description of a novel tissue biomarker of membranous nephropathy related to autoimmune diseases such as LN.
pubmed: 31061139 doi: 10.1681/ASN.2018080852
Devarapu, S. K., Lorenz, G., Kulkarni, O. P., Anders, H.-J. & Mulay, S. R. Cellular and molecular mechanisms of autoimmunity and lupus nephritis. Int. Rev. Cell Mol. Biol. 332, 43–154 (2017).
pubmed: 28526137 doi: 10.1016/bs.ircmb.2016.12.001
Hiepe, F. et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat. Rev. Rheumatol. 7, 170–178 (2011). This article reviews the profound role that long-lived plasma cells may have in LN, and highlights their potential as therapeutic targets.
pubmed: 21283146 doi: 10.1038/nrrheum.2011.1
Hiepe, F. & Radbruch, A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat. Rev. Nephrol. 12, 232–240 (2016).
pubmed: 26923204 doi: 10.1038/nrneph.2016.20
Huang, X. et al. Autologous hematopoietic stem cell transplantation for refractory lupus nephritis. Clin. J. Am. Soc. Nephrol. 14, 719–727 (2019).
pubmed: 30979713 doi: 10.2215/CJN.10570918
Alexander, T. et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 74, 1474–1478 (2015).
pubmed: 25710470 pmcid: 4484251 doi: 10.1136/annrheumdis-2014-206016
Sun, C. et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget 10, 2369–2383 (2019).
pubmed: 31040928 pmcid: 6481321 doi: 10.18632/oncotarget.26792
Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902–914 (2019).
pubmed: 31209404 pmcid: 6726437 doi: 10.1038/s41590-019-0398-x
Kang, S. et al. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J. Immunol. 198, 2602–2611 (2017).
pubmed: 28235864 pmcid: 5360485 doi: 10.4049/jimmunol.1600281
Der, E. et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat. Immunol. 20, 915–927 (2019).
pubmed: 31110316 pmcid: 6584054 doi: 10.1038/s41590-019-0386-1
Bethunaickan, R. et al. Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice. Arthritis Rheumatol. 66, 2246–2258 (2014).
pubmed: 24757019 pmcid: 4554534 doi: 10.1002/art.38679
Kidney disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013). The current global guideline for evaluation and management of CKD irrespective of its cause.
doi: 10.1038/kisup.2012.73
Low Birth Weight and Nephron Number Working Group. The impact of kidney development on the life course: a consensus document for action. Nephron 136, 3–49 (2017).
doi: 10.1159/000457967
Romagnani, P. et al. Chronic kidney disease. Nat. Rev. Dis. Primers 3, 17088 (2017).
pubmed: 29168475 doi: 10.1038/nrdp.2017.88
Mackay, M. et al. Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol. 71, 411–419 (2019). An analysis of multiple trial data sets presenting a proteinuria threshold that is associated with fortunate long-term outcomes.
pubmed: 30225865 doi: 10.1002/art.40724
Mageau, A. et al. The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun. Rev. 18, 733–737 (2019).
pubmed: 31059847 doi: 10.1016/j.autrev.2019.05.011
Mejía-Vilet, J. M. et al. Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus 25, 315–324 (2016).
pubmed: 26405028 doi: 10.1177/0961203315606985
Momtaz, M. et al. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. Lupus 26, 1564–1570 (2017).
pubmed: 28625079 doi: 10.1177/0961203317716320
Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841–845 (2010).
pubmed: 20647424 pmcid: 20647424 doi: 10.1126/science.1193032
Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345–350 (2010).
pubmed: 20635188 pmcid: 2921485 doi: 10.1007/s00439-010-0861-0
Freedman, B. I. et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 66, 390–396 (2014). A study that establishes the diagnostic value of APOL1 variants in predicting the progression of CKD in patients with LN.
pubmed: 24504811 pmcid: 4002759 doi: 10.1002/art.38220
Lin, C. P. et al. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun. 13, 232–238 (2012).
pubmed: 22189356 doi: 10.1038/gene.2011.82
Romagnani, P. et al. Next generation sequencing and functional analysis of patient urine renal progenitor-derived podocytes to unravel the diagnosis underlying refractory lupus nephritis. Nephrol. Dial. Transplant. 31, 1541–1545 (2016).
pubmed: 27325253 doi: 10.1093/ndt/gfw234
Mok, C.-C. Understanding lupus nephritis: diagnosis, management, and treatment options. Int. J. Womens Health 4, 213–222 (2012).
pubmed: 22675266 pmcid: 3367406 doi: 10.2147/IJWH.S28034
Tan, E. M. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus: revised criteria for SLE. Arthritis Rheum. 25, 1271–1277 (1982).
pubmed: 7138600 doi: 10.1002/art.1780251101
Petri, M. et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677–2686 (2012).
pubmed: 22553077 pmcid: 3409311 doi: 10.1002/art.34473
Aringer, M. et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78, 1151–1159 (2019).
pubmed: 31383717 doi: 10.1136/annrheumdis-2018-214819
Fine, D. M. et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int. 76, 1284–1288 (2009).
pubmed: 19759526 pmcid: 3093656 doi: 10.1038/ki.2009.344
Font, J. et al. Silent renal disease in systemic lupus erythematosus. Clin. Nephrol. 27, 283–288 (1987).
pubmed: 3497000
Gordon, C. et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 18, 257–263 (2009). This article provides guidance regarding LN classification and definitions of induction, response, flare and maintenance.
pubmed: 19213865 doi: 10.1177/0961203308100481
Bertsias, G. K. et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71, 1771–1782 (2012). This article provides EULAR/ERA–EDTA treatment recommendations for the management of LN. An update is in preparation.
pubmed: 22851469 pmcid: 3465859 doi: 10.1136/annrheumdis-2012-201940
Hahn, B. H. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64, 797–808 (2012). This article provides ACR treatment recommendations for the management of LN.
doi: 10.1002/acr.21664
Bihl, G. R., Petri, M. & Fine, D. M. Kidney biopsy in lupus nephritis: look before you leap. Nephrol. Dial. Transplant. 21, 1749–1752 (2006).
pubmed: 16632559 doi: 10.1093/ndt/gfl159
Tamirou, F. et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN nephritis trial. Lupus Sci. Med. 2, e000123 (2015).
pubmed: 26629352 pmcid: 4654096 doi: 10.1136/lupus-2015-000123
Ugolini-Lopes, M. R. et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci. Med 4, e000213 (2017).
pubmed: 29238603 pmcid: 5724342 doi: 10.1136/lupus-2017-000213
Dall’Era, M. et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort. Arthritis Rheumatol. 67, 1305–1313 (2015).
pubmed: 25605554 doi: 10.1002/art.39026
Zickert, A., Sundelin, B., Svenungsson, E. & Gunnarsson, I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci. Med. 1, e000018 (2014).
pubmed: 25379188 pmcid: 4213828 doi: 10.1136/lupus-2014-000018
Malvar, A. et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol. Dial. Transplant. 32, 1338–1344 (2017).
pubmed: 26250434 doi: 10.1093/ndt/gfv296
Parikh, S. V., Nagaraja, H. N., Hebert, L. & Rovin, B. H. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin. J. Am. Soc. Nephrol. 9, 279–284 (2014).
pubmed: 24262502 doi: 10.2215/CJN.05040513
Ioannidis, J. P. et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 57, 258–264 (2000).
pubmed: 10620207 doi: 10.1046/j.1523-1755.2000.00832.x
De Rosa, M. et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 94, 788–794 (2018). Zickert et al. (2014), Malvar et al. (2017) and De Rosa et al. (2018) demonstrate discordance between clinical outcome and histological findings following immunosuppressive treatment of LN.
pubmed: 30045812 doi: 10.1016/j.kint.2018.05.021
Appel, G. B., Silva, F. G., Pirani, C. L., Meltzer, J. I. & Estes, D. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine 57, 371–410 (1978).
pubmed: 682942 doi: 10.1097/00005792-197809000-00001
Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65, 521–530 (2004).
pubmed: 14717922 doi: 10.1111/j.1523-1755.2004.00443.x
Churg, J., Bernstein, J. & Glassock, R. J. Reviews and notes: nephrology: renal disease: classification and atlas of glomerular diseases. Ann. Intern. Med. 123, 80–80 (1995).
Pirani, C. L., Pollak, V. E. & Schwartz, F. D. The reproducibility of semiquantitative analyses of renal histology. Nephron 1, 230–237 (1964).
pubmed: 14263632 doi: 10.1159/000179336
Morel-Maroger, L. et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv. Nephrol. Necker Hosp. 6, 79–118 (1976).
pubmed: 139084
Austin, H. A. et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am. J. Med. 75, 382–391 (1983).
pubmed: 6351607 doi: 10.1016/0002-9343(83)90338-8
Schwartz, M. M. et al. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Am. J. Kidney Dis. 21, 374–377 (1993).
pubmed: 8465815 doi: 10.1016/S0272-6386(12)80263-0
Contreras, G. et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 14, 890–895 (2005).
pubmed: 16335581 doi: 10.1191/0961203305lu2238oa
Bajema, I. M. et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 93, 789–796 (2018).
pubmed: 29459092 doi: 10.1016/j.kint.2017.11.023
Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295–306 (2006).
pubmed: 16420554 doi: 10.1111/j.1538-7836.2006.01753.x
Daugas, E. et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J. Am. Soc. Nephrol. 13, 42–52 (2002).
pubmed: 11752020
Tektonidou, M. G., Sotsiou, F., Nakopoulou, L., Vlachoyiannopoulos, P. G. & Moutsopoulos, H. M. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 50, 2569–2579 (2004).
pubmed: 15334471 doi: 10.1002/art.20433
Gerhardsson, J. et al. Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. Arthritis Res. Ther. 17, 109 (2015).
pubmed: 25927214 pmcid: 4443508 doi: 10.1186/s13075-015-0614-5
Song, D. et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res. Ther. 15, R12 (2013).
pubmed: 23320601 pmcid: 3672792 doi: 10.1186/ar4142
Zheng, H. et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res. Ther. 11, R93 (2009).
pubmed: 19545416 pmcid: 2714149 doi: 10.1186/ar2736
Jordan, N. et al. Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients. Arthritis Care Res. 66, 725–731 (2014).
doi: 10.1002/acr.22200
Nielly, H. et al. Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. Nephrol. Dial. Transplant. https://doi.org/10.1093/ndt/gfz085 (2019).
doi: 10.1093/ndt/gfz08 pubmed: 31157889
Moroni, G. et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am. J. Kidney Dis. 43, 28–36 (2004).
pubmed: 14712424 doi: 10.1053/j.ajkd.2003.09.011
Frampton, G., Hicks, J. & Cameron, J. S. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int. 39, 1225–1231 (1991).
pubmed: 1716712 doi: 10.1038/ki.1991.155
Mehrani, T. & Petri, M. IgM anti-ß
pubmed: 21123325 doi: 10.3899/jrheum.100650
Bhandari, S. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. QJM 91, 401–409 (1998).
pubmed: 9709458 doi: 10.1093/qjmed/91.6.401
Stratta, P. et al. Catastrophic antiphospholipid syndromes in systemic lupus erythematosus. Ren. Fail. 21, 49–61 (1999).
pubmed: 10048117 doi: 10.3109/08860229909066969
Parodis, I. et al. Antiphospholipid antibodies in lupus nephritis. PLOS ONE 11, e0158076 (2016).
pubmed: 27336701 pmcid: 4919007 doi: 10.1371/journal.pone.0158076
Soliman, S. & Mohan, C. Lupus nephritis biomarkers. Clin. Immunol. 185, 10–20 (2017).
pubmed: 27498110 doi: 10.1016/j.clim.2016.08.001
Moroni, G. et al. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J. Immunol. Res. 2015, 106904 (2015).
pubmed: 25815344 pmcid: 4357044 doi: 10.1155/2015/106904
Olson, S. W. et al. Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. Clin. J. Am. Soc. Nephrol. 8, 1702–1708 (2013).
pubmed: 23833315 pmcid: 3789337 doi: 10.2215/CJN.01910213
Wakiguchi, H., Takei, S., Kubota, T., Miyazono, A. & Kawano, Y. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels. Clin. Rheumatol. 36, 433–437 (2017).
pubmed: 27900491 doi: 10.1007/s10067-016-3491-7 pmcid: 27900491
Kwon, O. C. et al. Predicting eventual development of lupus nephritis at the time of diagnosis of systemic lupus erythematosus. Semin. Arthritis Rheum. 48, 462–466 (2018).
pubmed: 29566965 doi: 10.1016/j.semarthrit.2018.02.012
Buyon, J. P. et al. Kidney outcomes and risk factors for nephritis (flare/de novo) in a multiethnic cohort of pregnant patients with lupus. Clin. J. Am. Soc. Nephrol. 12, 940–946 (2017).
pubmed: 28400421 pmcid: 5460714 doi: 10.2215/CJN.11431116
Marto, N. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 444–448 (2004).
pubmed: 15286009 pmcid: 1755385 doi: 10.1136/ard.2004.024943
Moroni, G. et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann. Rheum. Dis. 68, 234–237 (2009).
pubmed: 18718989 doi: 10.1136/ard.2008.094508
Julkunen, H., Ekblom-Kullberg, S. & Miettinen, A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol. Int. 32, 2445–2451 (2012).
pubmed: 21706294 doi: 10.1007/s00296-011-1962-3
Yang, X.-W., Tan, Y., Yu, F. & Zhao, M.-H. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol. Dial. Transplant. 27, 3552–3559 (2012).
pubmed: 22700716 doi: 10.1093/ndt/gfs179
Orbai, A.-M. et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 24, 42–49 (2015).
pubmed: 25124676 doi: 10.1177/0961203314547791
Fang, Q.-Y. et al. Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol. Dial. Transplant. 24, 172–178 (2008).
pubmed: 18697800 doi: 10.1093/ndt/gfn453
Tan, Y. et al. Detection of anti-C1q antibodies and anti-C1q globular head domain antibodies in sera from Chinese patients with lupus nephritis. Mol. Immunol. 46, 2178–2182 (2009).
pubmed: 19481805 doi: 10.1016/j.molimm.2009.04.030 pmcid: 19481805
Pang, Y. et al. Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis. Kidney Int. 90, 1357–1367 (2016). This study reports that the serum level of anti-C1q A08 antibodies correlated better with LN relapse than that of antibodies to other forms of C1q.
pubmed: 27745701 doi: 10.1016/j.kint.2016.08.010
Katsumata, Y. et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum. 63, 2436–2444 (2011).
pubmed: 21506094 doi: 10.1002/art.30401
Tan, Y. et al. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum. Immunol. 69, 840–844 (2008).
pubmed: 18852001 doi: 10.1016/j.humimm.2008.09.006
Sjöwall, C., Zickert, A., Skogh, T., Wetterö, J. & Gunnarsson, I. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res. Ther. 11, R188 (2009).
pubmed: 20003354 pmcid: 3003497 doi: 10.1186/ar2880
Li, Q.-y et al. Autoantibodies against C-reactive protein influence complement activation and clinical course in lupus nephritis. J. Am. Soc. Nephrol. 28, 3044–3054 (2017). This study provides a mechanistic link between autoantibody binding to modified C-reactive protein and complement factor H activity in LN.
pubmed: 28566480 pmcid: 5619952 doi: 10.1681/ASN.2016070735
Simon, J. A. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology 43, 220–224 (2003).
pubmed: 13130152 doi: 10.1093/rheumatology/keh024
Manson, J. J. et al. Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res. Ther. 11, R154 (2009).
pubmed: 19828047 pmcid: 2787270 doi: 10.1186/ar2831
Vikerfors, A. et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology 52, 501–509 (2013).
pubmed: 23159889 doi: 10.1093/rheumatology/kes252
Illei, G. G., Tackey, E., Lapteva, L. & Lipsky, P. E. Biomarkers in systemic lupus erythematosus: I. General overview of biomarkers and their applicability. Arthritis Rheum. 50, 1709–1720 (2004).
pubmed: 15188346 doi: 10.1002/art.20344
Rovin, B. H. et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16, 467–473 (2005).
pubmed: 15601744 doi: 10.1681/ASN.2004080658
Qi, S., Chen, Q., Xu, D., Xie, N. & Dai, Y. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis. Lupus 27, 1582–1590 (2018).
pubmed: 29720035 doi: 10.1177/0961203318773643
Zhang, X. et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int. 81, 401–406 (2012).
pubmed: 21993584 doi: 10.1038/ki.2011.354
Faurschou, M., Starklint, H., Halberg, P. & Jacobsen, S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J. Rheumatol. 33, 1563–1569 (2006).
pubmed: 16881113
Donadio, J. V., Holley, K. E., Ferguson, R. H. & Ilstrup, D. M. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N. Engl. J. Med. 299, 1151–1155 (1978).
pubmed: 309095 doi: 10.1056/NEJM197811232992102
Austin, H. A. 3rd et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314, 614–619 (1986). This landmark clinical trial from the NIH establishes intravenous cyclophosphamide therapy as the gold standard in the treatment of LN.
pubmed: 3511372 doi: 10.1056/NEJM198603063141004
Bono, L. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 92, 211–218 (1999).
pubmed: 10396609 doi: 10.1093/qjmed/92.4.211
Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide: immunosuppressive therapy in lupus nephritis. Arthritis Rheum. 46, 2121–2131 (2002). A randomized clinical trial that shows efficacy and safety of low-dose intravenous cyclophosphamide therapy (ELNT regimen) in the treatment of LN.
pubmed: 12209517 doi: 10.1002/art.10461
ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study: abatacept in lupus nephritis. Arthritis Rheumatol. 66, 3096–3104 (2014).
doi: 10.1002/art.38790
Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736–745 (2019).
pubmed: 30926722 doi: 10.1136/annrheumdis-2019-215089
Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N. Engl. J. Med. 343, 1156–1162 (2000).
pubmed: 11036121 doi: 10.1056/NEJM200010193431604
Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219–2228 (2005). A randomized clinical trial from the USA that shows non-inferiority of MMF compared with intravenously administered cyclophosphamide as an induction regimen in the treatment of LN.
pubmed: 16306519 doi: 10.1056/NEJMoa043731
Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009). A large global randomized clinical trial (ALMS) that shows efficacy of MMF as an induction agent in the treatment of LN.
pubmed: 19369404 pmcid: 2678035 doi: 10.1681/ASN.2008101028
Isenberg, D. et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49, 128–140 (2010).
pubmed: 19933596 doi: 10.1093/rheumatology/kep346
Soares, P. M. et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum. 56, 2352–2361 (2007).
pubmed: 17599762 doi: 10.1002/art.22660
Mok, C. C. et al. Overview of lupus nephritis management guidelines and perspective from Asia. Int. J. Rheum. Dis. 16, 625–636 (2013).
pubmed: 24382275 doi: 10.1111/1756-185X.12212
Zahr, N. et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 62, 2047–2054 (2010).
pubmed: 20506558
Lertdumrongluk, P. et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int. 78, 389–395 (2010).
pubmed: 20531457 doi: 10.1038/ki.2010.170
Luszczynska, P. et al. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. Eur. J. Clin. Pharmacol. 75, 371–379 (2019).
pubmed: 30430214 doi: 10.1007/s00228-018-2599-x
Pourafshar, N. et al. The utility of trough mycophenolic acid levels for the management of lupus nephritis. Nephrol. Dial. Transpl. 34, 83–89 (2019).
doi: 10.1093/ndt/gfy026
Mok, C. C. et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann. Rheum. Dis. 75, 30–36 (2016).
pubmed: 25550339 doi: 10.1136/annrheumdis-2014-206456
Chen, W. et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am. J. Kidney Dis. 57, 235–244 (2011).
pubmed: 21177013 doi: 10.1053/j.ajkd.2010.08.036
Liao, R. et al. Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLOS ONE 10, e0132724 (2015).
pubmed: 26161538 pmcid: 4498640 doi: 10.1371/journal.pone.0132724
Zhang, H. et al. Multitarget therapy for maintenance treatment of lupus nephritis. J. Am. Soc. Nephrol. 28, 3671–3678 (2017).
pubmed: 28760751 pmcid: 5698076 doi: 10.1681/ASN.2017030263
Liu, Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162, 18–26 (2015).
pubmed: 25383558 doi: 10.7326/M14-1030
Rovin, B. H. et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 95, 219–231 (2019).
pubmed: 30420324 doi: 10.1016/j.kint.2018.08.025
Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 64, 1215–1226 (2012). A randomized clinical trial comparing safety and efficacy of rituximab added to the standard-of-care immunosuppressive therapy in the treatment of LN. The study did not meet the primary end points.
pubmed: 22231479 doi: 10.1002/art.34359
Gomez Mendez, L. M. et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin. J. Am. Soc. Nephrol. 13, 1502–1509 (2018).
pubmed: 30089664 pmcid: 6218830
Parodis, I. et al. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. Lupus 27, 1470–1478 (2018).
pubmed: 29783918 doi: 10.1177/0961203318777116
Carter, L. M., Isenberg, D. A. & Ehrenstein, M. R. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65, 2672–2679 (2013).
pubmed: 23839909
Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).
pubmed: 21296403 doi: 10.1016/S0140-6736(10)61354-2
Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).
pubmed: 22127708 pmcid: 5007058 doi: 10.1002/art.30613
Dooley, M. et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22, 63–72 (2013).
pubmed: 23263865 doi: 10.1177/0961203312465781
GSK. GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis. prnewswire.com https://www.prnewswire.com/news-releases/gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis-300976537.html (2019).
Cao, H. et al. The efficacy and safety of leflunomide for the treatment of lupus nephritis in Chinese patients: systematic review and meta-analysis. PLOS ONE 10, e0144548 (2015).
doi: 10.1371/journal.pone.0144548
Grootscholten, C. et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 70, 732–742 (2006).
pubmed: 16820790 doi: 10.1038/sj.ki.5001630
Moroni, G., Quaglini, S., Maccario, M., Banfi, G. & Ponticelli, C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 50, 2047–2053 (1996).
pubmed: 8943489 doi: 10.1038/ki.1996.528
Illei, G. G. et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 46, 995–1002 (2002).
pubmed: 11953977 doi: 10.1002/art.10142
Contreras, G. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971–980 (2004).
pubmed: 14999109 doi: 10.1056/NEJMoa031855
Houssiau, F. A. et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61–64 (2010).
pubmed: 19155235 doi: 10.1136/ard.2008.102533
Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886–1895 (2011). A randomized clinical trial showing greater efficacy of MMF than of azathioprine as a maintenance agent in preventing relapses in patients with LN.
pubmed: 22087680 doi: 10.1056/NEJMoa1014460
Tamirou, F. et al. Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann. Rheum. Dis. 75, 526–531 (2016).
pubmed: 25757867 doi: 10.1136/annrheumdis-2014-206897
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int. Suppl. 2, 139–274 (2012).
doi: 10.1038/kisup.2012.9
Palmer, S. C. et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am. J. Kidney Dis. 70, 324–336 (2017).
pubmed: 28233655 doi: 10.1053/j.ajkd.2016.12.008
Floege, J. et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 95, 268–280 (2019).
pubmed: 30665568 doi: 10.1016/j.kint.2018.10.018
Malvar, A. et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int. 97, 156–162 (2020).
pubmed: 31685314 doi: 10.1016/j.kint.2019.07.018
Kraft, S. W., Schwartz, M. M., Korbet, S. M. & Lewis, E. J. Glomerular podocytopathy in patients with systemic lupus erythematosus. J. Am. Soc. Nephrol. 16, 175–179 (2005).
pubmed: 15548564 doi: 10.1681/ASN.2004050350
Mok, C., Cheung, T. & Lo, W. Minimal mesangial lupus nephritis: a systematic review. Scand. J. Rheumatol. 39, 181–189 (2010).
pubmed: 20166847 doi: 10.3109/03009740903456300
Radhakrishnan, J. et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 77, 152–160 (2010).
pubmed: 19890271 doi: 10.1038/ki.2009.412
Austin, H. A., Illei, G. G., Braun, M. J. & Balow, J. E. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20, 901–911 (2009).
pubmed: 19297556 pmcid: 2663831 doi: 10.1681/ASN.2008060665
Praga, M., Barrio, V., Juárez, G. F. & Luño, J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71, 924–930 (2007).
pubmed: 17377504 doi: 10.1038/sj.ki.5002215
Howman, A. et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381, 744–751 (2013).
pubmed: 23312808 pmcid: 3590447 doi: 10.1016/S0140-6736(12)61566-9
Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36–46 (2019).
pubmed: 31269364 doi: 10.1056/NEJMoa1814427
Jayne, D. et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13, 168–176 (2004).
pubmed: 15119545 doi: 10.1191/0961203304lu525oa
Lee, S.-J., Silverman, E. & Bargman, J. M. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat. Rev. Nephrol. 7, 718–729 (2011).
pubmed: 22009248 doi: 10.1038/nrneph.2011.150
Marmor, M. F., Kellner, U., Lai, T. Y. Y., Lyons, J. S. & Mieler, W. F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118, 415–422 (2011).
pubmed: 21292109 doi: 10.1016/j.ophtha.2010.11.017
Kim, J.-W. et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. J. Rheumatol. 44, 1674–1679 (2017).
pubmed: 28864645 doi: 10.3899/jrheum.170158
Melles, R. B. & Marmor, M. F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453–1460 (2014).
pubmed: 25275721 doi: 10.1001/jamaophthalmol.2014.3459
Khubchandani, S. R. & Bichle, L. S. Hydroxychloroquine-induced phospholipidosis in a case of SLE: the wolf in zebra clothing. Ultrastruct. Pathol. 37, 146–150 (2013).
pubmed: 23573895 doi: 10.3109/01913123.2012.751950
Korbet, S. M. et al. Factors predictive of outcome in severe lupus nephritis. Am. J. Kidney Dis. 35, 904–914 (2000).
pubmed: 10793026 doi: 10.1016/S0272-6386(00)70262-9
Chen, Y. E., Korbet, S. M., Katz, R. S., Schwartz, M. M. & Lewis, E. J. Value of a complete or partial remission in severe lupus nephritis. Clin. J. Am. Soc. Nephrol. 3, 46–53 (2008).
pubmed: 18003764 pmcid: 2390978 doi: 10.2215/CJN.03280807
Fung, W. A., Su, J. & Touma, Z. Predictors of good long-term renal outcomes in lupus nephritis: results from a single lupus cohort. Biomed. Res. Int. 2017, 5312960 (2017).
pubmed: 28904963 pmcid: 5585546 doi: 10.1155/2017/5312960
Arriens, C. et al. Prognostic significance of repeat biopsy in lupus nephritis: histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin. Immunol. 185, 3–9 (2017).
pubmed: 27923701 doi: 10.1016/j.clim.2016.11.019
Narváez, J. et al. The value of repeat biopsy in lupus nephritis flares. Medicine 96, e7099 (2017).
pubmed: 28614228 pmcid: 5478313 doi: 10.1097/MD.0000000000007099
Weng, C.-T. et al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J. Clin. Rheumatol. 19, 252–258 (2013).
pubmed: 23872548 doi: 10.1097/RHU.0b013e31829d5017
Park, J. W. et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann. Rheum. Dis. 77, 644–649 (2018).
pubmed: 29092853 doi: 10.1136/annrheumdis-2017-211796
Park, J. W. et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res. Ther. 21, 207 (2019).
pubmed: 31521185 pmcid: 6744623 doi: 10.1186/s13075-019-1996-6
Jeffries, M. et al. Sulpha allergy in lupus patients: a clinical perspective. Lupus 17, 202–205 (2008).
pubmed: 18372360 doi: 10.1177/0961203307086640
Pope, J., Jerome, D., Fenlon, D., Krizova, A. & Ouimet, J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J. Rheumatol. 30, 480–484 (2003).
pubmed: 12610805
Utsunomiya, M. et al. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res. Ther. 19, 7 (2017).
pubmed: 28100282 pmcid: 5241919 doi: 10.1186/s13075-016-1206-8
Suyama, Y. et al. Safety and efficacy of upfront graded administration of trimethoprim–sulfamethoxazole in systemic lupus erythematosus: a retrospective cohort study. Mod. Rheumatol. 26, 557–561 (2016).
pubmed: 26587755 doi: 10.3109/14397595.2015.1112467
Gaitonde, S. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann. Rheum. Dis. 61, 251–253 (2002).
pubmed: 11830432 pmcid: 1754016 doi: 10.1136/ard.61.3.251
Liaw, Y.-F. et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 6, 531–561 (2012).
pubmed: 26201469 doi: 10.1007/s12072-012-9365-4
Maillefert, J. F. et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology 38, 978–983 (1999).
pubmed: 10534549 doi: 10.1093/rheumatology/38.10.978
Maillefert, J. F., Tavernier, C., Sibilia, J. & Vignon, E. Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano et al and the letter by Senecal et al. Arthritis Rheum. 43, 468–469 (2000).
pubmed: 10693893 doi: 10.1002/1529-0131(200002)43:2<468::AID-ANR32>3.0.CO;2-K
Kuruma, K. A., Borba, E. F., Lopes, M. H., de Carvalho, J. F. & Bonfa, E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 16, 350–354 (2007).
pubmed: 17576737 doi: 10.1177/0961203307078225
Sarin, S. K. et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1–98 (2016).
pubmed: 26563120 doi: 10.1007/s12072-015-9675-4
Singh, R. R. & Yen, E. Y. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus 27, 1577–1581 (2018).
pubmed: 30016928 pmcid: 6082727 doi: 10.1177/0961203318786436
Yen, E. Y. et al. 46-Year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population-based study. Ann. Intern. Med. 167, 777–785 (2017).
pubmed: 29086801 pmcid: 6188647 doi: 10.7326/M17-0102
Yurkovich, M., Vostretsova, K., Chen, W. & Avina-Zubieta, J. A. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res. 66, 608–616 (2014).
doi: 10.1002/acr.22173
Rahman, P., Gladman, D. D., Urowitz, M. B., Hallett, D. & Tam, L. S. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10, 93–96 (2001).
pubmed: 11237132 doi: 10.1191/096120301670679959
Nikpour, M., Urowitz, M. B. & Gladman, D. D. Premature atherosclerosis in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 31, 329–354 (2005).
pubmed: 15922149 doi: 10.1016/j.rdc.2005.01.001
Fasano, S., Pierro, L., Pantano, I., Iudici, M. & Valentini, G. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J. Rheumatol. 44, 1032–1038 (2017).
pubmed: 28507183 doi: 10.3899/jrheum.161351
Iudici, M. et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology 55, 1623–1630 (2016).
pubmed: 27247433 doi: 10.1093/rheumatology/kew231
Piepoli, M. F. et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 37, 2315–2381 (2016).
pubmed: 27222591 pmcid: 4986030 doi: 10.1093/eurheartj/ehw106
Gaziano, J. M. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392, 1036–1046 (2018).
pubmed: 30158069 doi: 10.1016/S0140-6736(18)31924-X
Bowman, L. et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med. 379, 1529–1539 (2018).
pubmed: 30146931 doi: 10.1056/NEJMoa1804988
Petri, M. A., Kiani, A. N., Post, W., Christopher-Stine, L. & Magder, L. S. Lupus atherosclerosis prevention study (LAPS). Ann. Rheum. Dis. 70, 760–765 (2011).
pubmed: 21177297 doi: 10.1136/ard.2010.136762
Schanberg, L. E. et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 64, 285–296 (2012).
pubmed: 22031171 pmcid: 4074430 doi: 10.1002/art.30645
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2, 279–335 (2012).
doi: 10.1038/kisup.2012.37
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 7, 1–59 (2017).
doi: 10.1016/j.kisu.2017.04.001
Mok, C. C., Mak, A. & Ma, K. M. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14, 106–112 (2005).
pubmed: 15751814 doi: 10.1191/0961203305lu2039oa
Uaratanawong, S., Deesomchoke, U., Lertmaharit, S. & Uaratanawong, S. Bone mineral density in premenopausal women with systemic lupus erythematosus. J. Rheumatol. 30, 2365–2368 (2003).
pubmed: 14677178
Ramsey-Goldman, R. et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 42, 882–890 (1999).
pubmed: 10323443 doi: 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C
Oleksik, A. et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J. Bone Miner. Res. 15, 1384–1392 (2000).
pubmed: 10893688 doi: 10.1359/jbmr.2000.15.7.1384
Hasserius, R., Karlsson, M. K., Nilsson, B. E., Redlund-Johnell, I. & Johnell, O. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos. Int. 14, 61–68 (2003).
pubmed: 12577186 doi: 10.1007/s00198-002-1316-9
Buckley, L. et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 69, 1521–1537 (2017).
pubmed: 28585373 doi: 10.1002/art.40137
Buyon, J. P. et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 142, 953–962 (2005).
pubmed: 15968009 doi: 10.7326/0003-4819-142-12_Part_1-200506210-00004
Mok, C. C., To, C. H., Mak, A. & Ma, K. M. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum. 52, 3997–4002 (2005).
pubmed: 16320346 doi: 10.1002/art.21477
Crew, R. J., Radhakrishnan, J. & Appel, G. Complications of the nephrotic syndrome and their treatment. Clin. Nephrol. 62, 245–259 (2004).
pubmed: 15524054 doi: 10.5414/CNP62245
Lee, T. et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int. 85, 1412–1420 (2014).
pubmed: 24336031 doi: 10.1038/ki.2013.476
Mercadal, L. et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol. Dial. Transpl. 17, 1771–1778 (2002).
doi: 10.1093/ndt/17.10.1771
Mantha, S. et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. Br. Med. J. 345, e4944 (2012).
doi: 10.1136/bmj.e4944
Mok, C. C., Lau, C. S. & Wong, R. W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41, 831–837 (1998).
pubmed: 9588734 doi: 10.1002/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6
Somers, E. C., Marder, W., Christman, G. M., Ognenovski, V. & McCune, W. J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 52, 2761–2767 (2005).
pubmed: 16142702 doi: 10.1002/art.21263
Tamirou, F. et al. Brief report: the Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Müllerian hormone. Arthritis Rheumatol. 69, 1267–1271 (2017).
pubmed: 28235250 doi: 10.1002/art.40079
Wasserman, S. & Clowse, M. E. B. in Contraception and Pregnancy in Patients with Rheumatic Disease (eds Sammaritano, L. R. & Bermas, B. L.) 79–97 (Springer, 2014).
Clowse, M. E. B., Magder, L. S., Witter, F. & Petri, M. Early risk factors for pregnancy loss in lupus. Obstet. Gynecol. 107, 293–299 (2006).
pubmed: 16449114 doi: 10.1097/01.AOG.0000194205.95870.86
Liu, J. et al. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women. J. Materrn. Fetal Neonatal Med. 25, 261–266 (2012).
doi: 10.3109/14767058.2011.572310
Clowse, M. E. B., Magder, L. S., Witter, F. & Petri, M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 52, 514–521 (2005).
pubmed: 15692988 doi: 10.1002/art.20864
Smyth, A. et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin. J. Am. Soc. Nephrol. 5, 2060–2068 (2010).
pubmed: 20688887 pmcid: 3001786 doi: 10.2215/CJN.00240110
Ruffatti, A. et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb. Haemost. 96, 337–341 (2006).
pubmed: 16953276 doi: 10.1160/TH06-05-0287
Buyon, J. P. et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann. Intern. Med. 163, 153–163 (2015). This large prospective multiethnic study provides an approach to identify pregnant patients with SLE who are at risk of adverse outcomes.
pubmed: 26098843 pmcid: 5113288 doi: 10.7326/M14-2235
Clowse, M. E. B. & Grotegut, C. Racial and ethnic disparities in the pregnancies of women with systemic lupus erythematosus: lupus pregnancy and racial disparities. Arthritis Care Res. 68, 1567–1572 (2016).
doi: 10.1002/acr.22847
Skorpen, C. G. et al. Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann. Rheum. Dis. 77, 264–269 (2018). This study compares the frequency of serious adverse outcomes in pregnancy in patients with active and inactive SLE with the general population in a national registry and emphasizes that active SLE enhances the risk of these outcomes.
pubmed: 29092851 doi: 10.1136/annrheumdis-2017-211641
Izmirly, P. M., Rivera, T. L. & Buyon, J. P. Neonatal lupus syndromes. Rheum. Dis. Clin. North Am. 33, 267–285 (2007).
pubmed: 17499707 doi: 10.1016/j.rdc.2007.02.005
Saavedra, M. A. et al. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. Clin. Rheumatol. 31, 813–819 (2012).
pubmed: 22278163 doi: 10.1007/s10067-012-1941-4
Wagner, S. et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 18, 342–347 (2009).
pubmed: 19276302 pmcid: 2724676 doi: 10.1177/0961203308097575
Bramham, K. et al. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J. Rheumatol. 38, 1906–1913 (2011).
pubmed: 21632681 doi: 10.3899/jrheum.100997
Palmsten, K. et al. Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: daily and cumulative dose. Pharmacoepidemiol. Drug Saf. 27, 430–438 (2018).
pubmed: 29488292 pmcid: 6039094 doi: 10.1002/pds.4410
Meads, C. et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol. Assess. 12, iii–270 (2008).
pubmed: 18462577 doi: 10.3310/hta12060
ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. Obstet. Gynecol. 132, e44–e52 (2018).
doi: 10.1097/AOG.0000000000002708
Ware, J. E. & Sherbourne, C. D. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med. Care 30, 473–483 (1992).
pubmed: 1593914 doi: 10.1097/00005650-199206000-00002
Wang, C., Mayo, N. E. & Fortin, P. R. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J. Rheumatol. 28, 525–532 (2001).
pubmed: 11296953
EuroQol Group. EuroQol — a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990).
doi: 10.1016/0168-8510(90)90421-9
Wolfe, F., Michaud, K., Li, T. & Katz, R. S. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J. Rheumatol. 37, 296–304 (2010).
pubmed: 20032098 doi: 10.3899/jrheum.090778
Webster, K., Cella, D. & Yost, K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual. Life Outcomes 1, 79 (2003).
pubmed: 14678568 pmcid: 317391 doi: 10.1186/1477-7525-1-79
Kosinski, M., Gajria, K., Fernandes, A. & Cella, D. Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus. Lupus 22, 422–430 (2013).
pubmed: 23423250 doi: 10.1177/0961203313476360
Leong, K. P. et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 44, 1267–1276 (2005).
pubmed: 15797980 doi: 10.1093/rheumatology/keh605
McElhone, K. et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 57, 972–979 (2007).
pubmed: 17665467 doi: 10.1002/art.22881
Jolly, M. et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin. Arthritis Rheum. 42, 56–65 (2012).
pubmed: 22480408 doi: 10.1016/j.semarthrit.2011.12.005
Jolly, M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J. Rheumatol. 32, 1706–1708 (2005).
pubmed: 16142864
Mok, C. C. Treat-to-target in systemic lupus erythematosus: are we there yet? Expert. Rev. Clin. Pharmacol. 9, 675–680 (2016).
pubmed: 26809011 doi: 10.1586/17512433.2016.1146589
van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73, 958–967 (2014).
pubmed: 24739325 doi: 10.1136/annrheumdis-2013-205139
Mazzoni, D., Cicognani, E. & Prati, G. Health-related quality of life in systemic lupus erythematosus: a longitudinal study on the impact of problematic support and self-efficacy. Lupus 26, 125–131 (2017). This study indicates that the HRQOL of patients with SLE is influenced by self-efficacy in the management of the disease and problematic support.
pubmed: 27125289 doi: 10.1177/0961203316646459
Williams, E. M. et al. Intervention to improve quality of life for African-American lupus patients (IQAN): study protocol for a randomized controlled trial of a unique a la carte intervention approach to self-management of lupus in African Americans. BMC Health Serv. Res. 16, 339 (2016).
pubmed: 27485509 pmcid: 4971708 doi: 10.1186/s12913-016-1580-6
Yazdany, J. & Yelin, E. Health-related quality of life and employment among persons with systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 36, 15–32 (2010).
pubmed: 20202589 pmcid: 2833285 doi: 10.1016/j.rdc.2009.12.006
Kuriya, B., Gladman, D. D., Ibañez, D. & Urowitz, M. B. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum. 59, 181–185 (2008).
pubmed: 18240183 doi: 10.1002/art.23339
Friedman, A. W. et al. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. Arthritis Care Res. 12, 256–266 (1999).
pubmed: 10689990 doi: 10.1002/1529-0131(199908)12:4<256::AID-ART4>3.0.CO;2-G
Thumboo, J. et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J. Rheumatol. 27, 1414–1420 (2000).
pubmed: 10852263
Devins, G. M. & Edworthy, S. M. Illness intrusiveness explains race-related quality-of-life differences among women with systemic lupus erythematosus. Lupus 9, 534–541 (2000).
pubmed: 11035420 doi: 10.1177/096120330000900710
Doria, A. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology 43, 1580–1586 (2004).
pubmed: 15367746 doi: 10.1093/rheumatology/keh392
Dobkin, P. L. et al. Quality of life in systemic lupus erythematosus patients during more and less active disease states: differential contributors to mental and physical health. Arthritis Care Res. 12, 401–410 (1999).
pubmed: 11081011 doi: 10.1002/1529-0131(199912)12:6<401::AID-ART8>3.0.CO;2-F
Medeiros, M. M. C. et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur. J. Intern. Med. 19, 122–128 (2008).
pubmed: 18249308 doi: 10.1016/j.ejim.2007.06.012
Jolly, M. et al. Disease-specific quality of life in patients with lupus nephritis. Lupus 27, 257–264 (2018). These international, cross-sectional data from a large cohort of patients with SLE demonstrate that patients with active LN have worse quality of life than those with inactive LN.
pubmed: 28728507 doi: 10.1177/0961203317717082
Chaigne, B. et al. Impact of disease activity on health-related quality of life in systemic lupus erythematosus — a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol. 18, 17 (2017). This cross-sectional study of the Swiss SLE Cohort indicates that the impact of disease activity on HRQOL dimensions depends on specific Safety of Estrogens in Lupus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) system components, namely, musculoskeletal, renal and immunological manifestations of the disease.
pubmed: 28351341 pmcid: 5371245 doi: 10.1186/s12865-017-0200-5
Vu, T. V. & Escalante, A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J. Rheumatol. 26, 2595–2601 (1999).
pubmed: 10606368
Clarke, A. E. et al. SLE patients with renal damage incur higher health care costs. Rheumatology 47, 329–333 (2007).
doi: 10.1093/rheumatology/kem373
Appenzeller, S. et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J. Rheumatol. 36, 947–952 (2009).
pubmed: 19369453 doi: 10.3899/jrheum.080822
Daleboudt, G. M. N., Berger, S. P., Broadbent, E. & Kaptein, A. A. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychol. Health Med. 16, 393–404 (2011).
pubmed: 21749237 doi: 10.1080/13548506.2011.554566
Tse, K. C., Tang, C. S., Lio, W. I., Lam, M. F. & Chan, T. M. Quality of life comparison between corticosteroid-and-mycofenolate mofetil and corticosteroid-and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 15, 371–379 (2006).
pubmed: 16830884 doi: 10.1191/0961203306lu2307xx
Grootscholten, C. et al. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/methylprednisolone in a randomized controlled trial. J. Rheumatol. 34, 1699–1707 (2007).
pubmed: 17659757
Parodis, I. et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res. 71, 811–821 (2019).
doi: 10.1002/acr.23718
Alarcón-Riquelme, M. E. New attempts to define and clarify lupus. Curr. Rheumatol. Rep. 21, 11 (2019).
pubmed: 30806825 pmcid: 6394445 doi: 10.1007/s11926-019-0810-4
Mysler, E. F. et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study: ocrelizumab in lupus nephritis. Arthritis Rheum. 65, 2368–2379 (2013).
pubmed: 23740801 doi: 10.1002/art.38037
Furie, R. et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study: abatacept in lupus nephritis. Arthritis Rheumatol. 66, 379–389 (2014).
pubmed: 24504810 doi: 10.1002/art.38260
Isenberg, D. et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74, 2006–2015 (2015).
pubmed: 24951103 doi: 10.1136/annrheumdis-2013-205067
Furie, R. et al. in Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 176–177 (BMJ and European League Against Rheumatism, 2018).
Rovin, B. et al. A phase 2 randomized, controlled study of obinutuzumab with mycophenolate and corticosteroids inproliferative lupus nephritis (abstract FR-OR136). Presented at Proc. American Society of Nephrology Kidney Week 2019.
Alunno, A., Padjen, I., Fanouriakis, A. & Boumpas, D. T. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells 8, E898 (2019).
pubmed: 31443172 doi: 10.3390/cells8080898
Anders, H.-J., Jayne, D. R. W. & Rovin, B. H. Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat. Rev. Nephrol. 12, 205–216 (2016).
pubmed: 26804020 doi: 10.1038/nrneph.2015.206
Jayne, D. R. W. et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 2756–2767 (2017).
pubmed: 28400446 pmcid: 5576933 doi: 10.1681/ASN.2016111179
Houssiau, F. A. Time to change the primary outcome of lupus trials. Ann. Rheum. Dis. 78, 581–582 (2019).
pubmed: 29921574 doi: 10.1136/annrheumdis-2018-213788
van Vollenhoven, R. et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann. Rheum. Dis. 76, 554–561 (2017).
pubmed: 27884822 doi: 10.1136/annrheumdis-2016-209519
Anders, H.-J. & Rovin, B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 90, 493–501 (2016).
pubmed: 27378475 doi: 10.1016/j.kint.2016.05.017

Auteurs

Hans-Joachim Anders (HJ)

Division of Nephrology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.

Ramesh Saxena (R)

Division of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Ming-Hui Zhao (MH)

Renal Division, Peking University First Hospital, Beijing, China.
Peking-Tsinghua Center for Life Sciences, Beijing, China.

Ioannis Parodis (I)

Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Rheumatology, Karolinska University Hospital, Stockholm, Sweden.

Jane E Salmon (JE)

Division of Rheumatology, Department of Medicine, Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, USA.

Chandra Mohan (C)

Biomedical Engineering & Medicine, University of Houston, Houston, TX, USA. cmohan@central.uh.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Cytodiagnostic › Biopsie › Lupus nephritis.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de la calcineurine › Lupus nephritis.
questionsmedicales.fr › Composés chimiques organiques › Composés organiques du phosphore › Phosphoramides › Moutardes phosphoramide › Cyclophosphamide › Lupus nephritis.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Lupus nephritis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Lupus nephritis.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › Lupus nephritis.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › Lupus nephritis.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › Glomérulonéphrite lupique › Lupus nephritis.
questionsmedicales.fr › Lipides › Acides gras › Acide mycophénolique › Lupus nephritis.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Lupus nephritis.